Skip to nav Skip to content
  • Cancer Type: Malignant Hematology
  • Study Type: Treatment
  • NCT#: NCT05371093
  • Phase: Phase III
Learn More
  • Overview

    Study Title:

    A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma


    The goal of this clinical study is test how well the study drug, axicabtagene ciloleucel, works in participants with relapsed/refractory follicular lymphoma


    Primary Objective: The primary objective of this study is to determine if axicabtagene ciloleucel is superior to SOCT, as measured by PFS per a blinded independent radiologic review committee (hereafter referred to as blinded central assessment) in subjects with r/r FL. Secondary Objectives: The secondary objective of this study is to further characterize the efficacy and safety profile and patient reported outcomes associated with axicabtagene ciloleucel compared with SOCT. Exploratory Objectives: - To characterize the pharmacokinetic profile of axicabtagene ciloleucel in subjects with r/r FL (including those with high-risk disease), as measured by anti-CD19 CAR T-cell expansion and persistence in blood - To characterize the levels of serum/plasma analytes (including cytokines) as well as minimal residual disease (MRD) over time - To evaluate impact of disease and treatment on work productivity and activity

  • Treatments


    Cell Therapy; Chemotherapy (NOS); Therapy (NOS)


    Adriamycin (doxorubicin); Axicabtagene Ciloleucel (Yescarta); Bendamustine (); CC-5013 (Lenalidomide); Lenalidomide (Revlimid); Rituxan (rituximab); Vincristine (); cyclophosphamide (); cytoxan (cyclophosphamide); doxorubicin (); fludarabine (Fludarabine phosphate); prednisone (); rituximab ()

  • Inclusion Criteria

      Key Inclusion Criteria:
    • Age 18 or older
    • Histologically-confirmed follicular lymphoma (FL) (Grade 1, 2, or 3a)
    • Relapsed/refractory (R/r) disease after first-line chemoimmunotherapy and high-risk disease with relapse or progression within >24 months of the initial course of chemoimmunotherapy (ie, POD24), Or r/r disease after greater than or equal to 2 prior systemic lines of therapy
    • Clinical indication for treatment.
    • At least 1 measurable lesion per the Lugano Classification {Cheson 2014}
    • Adequate renal, hepatic, pulmonary, and cardiac function
    • Other criteria apply
  • Exclusion Criteria

      Exclusion Criteria:
    • Transformed Follicular Lymphoma (FL)
    • FL Grade 3b
    • Prior CD19-targeted therapy
    • Prior CAR therapy or other genetically modified T-cell therapy
    • Uncontrolled fungal, bacterial, viral, or other infection
    • Active Infection with human immunodeficiency virus, hepatitis B virus or hepatitis C virus
    • History or presence of a central nervous system (CNS) disorder.
    • History of autoimmune disease
    • Known history or CNS lymphoma involvement
    • Cardiac lymphoma involvement
    • History of clinically significant cardiac disease 6 months before randomization
    • Neuropathy greater than Grade 2
    • Females who are pregnant or breastfeeding
    • Individuals of both genders who are not willing to practice birth control
    • Other criteria apply

If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.

Clinical Trial Search